

**Supplementary Table 10.** Baseline characteristics of full cohort for a quarantine period of 6 weeks according drug exposure categories

Characteristic	No treatment (n=423)	OAC exposure (n=260)	OAC partial exposure (n=144)	OAC continuous exposure (n=116)
<b>Sociodemographics*</b>				
Age (yr)	83.6±5.8	81.7±5.8	81.6±6.1 <sup>†</sup>	81.9±5.4 <sup>*</sup>
Male sex	200 (47.3)	120 (46.1)	64 (44.4)	56 (48.3)
<b>Prior exposure (3-mo prior ICH index)</b>				
Anticoagulants	292 (69.0)	233 (89.6)	127 (88.2) <sup>†</sup>	106 (91.4) <sup>*</sup>
Warfarine	280 (66.2)	214 (82.3)	116 (80.6) <sup>†</sup>	98 (84.5) <sup>*</sup>
DOACs	14 (3.3)	21 (8.1)	12 (8.3) <sup>†</sup>	9 (7.8) <sup>*</sup>
Antiplatelet agents	167 (39.5)	83 (31.9)	52 (36.1)	31 (26.7) <sup>*</sup>
ASA low dose	155 (36.6)	74 (28.5)	45 (31.2)	29 (25.0) <sup>*</sup>
Clopidogrel	27 (6.4)	18 (6.9)	13 (9.0)	5 (4.3)
<b>Co-morbidities (ICH index and 1-yr prior)</b>				
Hypertension	366 (86.5)	218 (83.8)	122 (84.7)	96 (82.8)
Dyslipidemia	152 (35.9)	130 (50.0)	72 (50.0) <sup>†</sup>	58 (50.0) <sup>*</sup>
Diabetes	130 (30.7)	81 (31.1)	36 (25.0)	45 (38.8)
Coronary artery disease	272 (64.3)	168 (64.6)	92 (63.9)	76 (65.5)
Acute myocardial infarction	27 (6.4)	21 (8.1)	14 (9.7)	7 (6.0)
Chronic heart failure	147 (34.7)	104 (40.0)	52 (36.1)	52 (44.8) <sup>*</sup>
Cerebrovascular disease including TIA in 5-yr period	231 (54.6)	129 (49.6)	70 (48.6)	59 (50.9)
Peripheral vascular disease	85 (20.1)	65 (25.0)	32 (22.2)	33 (28.4)
Chronic renal failure	168 (39.7)	105 (40.4)	53 (36.8)	52 (44.8)
Acute renal failure	75 (17.7)	40 (15.4)	21 (14.6)	19 (16.4)
Chronic obstructive pulmonary disease/asthma	130 (30.7)	78 (30.0)	38 (26.4)	40 (34.5)
Prior major bleeding (excluding ICH) in 5-yr period	39 (9.2)	27 (10.4)	16 (11.1)	11 (9.5)
Liver disease	10 (2.4)	7 (2.7)	3 (2.1)	4 (3.4)
Systemic embolism	5 (1.2)	5 (1.9)	4 (2.8)	1 (0.9)
<b>Medications (3-mo prior ICH index)<sup>§</sup></b>				
β-Blockers	245 (57.9)	157 (60.4)	84 (58.3)	73 (62.9)
Calcium channel blockers	161 (38.1)	109 (41.9)	57 (39.6)	52 (44.8)
Inhibitors of renin-angiotensin system	206 (48.7)	126 (48.5)	67 (46.5)	59 (50.9)
Diuretics	229 (54.1)	152 (58.5)	81 (56.2)	71 (61.2)
Loop diuretics	193 (45.6)	122 (46.9)	66 (45.8)	56 (48.3)
Statin	202 (47.7)	149 (57.3)	81 (56.2)	68 (58.6) <sup>*</sup>
Antidiabetics	98 (23.2)	69 (26.5)	32 (22.2)	37 (31.9)
Antidepressants	105 (24.8)	56 (21.5)	27 (18.7)	29 (25.0)
Proton pump inhibitors	198 (46.8)	132 (50.8)	68 (47.2)	64 (55.2)
Digoxin	99 (23.4)	80 (30.8)	44 (30.6)	36 (31.0)
Amiodarone	49 (11.6)	39 (15.0)	21 (14.6)	18 (15.5)
<b>CHA<sub>2</sub>DS<sub>2</sub>-VASc score (ICH index and 1-yr prior)<sup>§</sup></b>				
3.9±1.3	3.9±1.3	3.9±1.3	3.9±1.3	3.9±1.3
1	1 (0.2)	7 (2.7)	5 (3.5) <sup>†</sup>	2 (1.7)
2	53 (12.5)	20 (7.7)	9 (6.3) <sup>†</sup>	11 (9.5)
3	110 (26.0)	72 (27.7)	43 (29.9) <sup>†</sup>	29 (25.0)
4–9	259 (61.2)	161 (61.9)	87 (60.4) <sup>†</sup>	74 (63.8)

Supplementary Table 10. Continued

Characteristic	No treatment (n=423)	OAC exposure (n=260)	OAC partial exposure (n=144)	OAC continuous exposure (n=116)
HAS-BLED score (ICH index and 1-yr prior) <sup>  </sup>	2.6±1.1	2.6±1.1	2.7±1.1	2.6±1.1
<3.0	219 (51.8)	141 (54.2)	74 (51.4)	67 (57.8)
≥3.0	204 (48.2)	119 (45.8)	70 (48.6)	49 (42.2)
Charlson score (ICH index and 1-yr prior index) <sup>§</sup>				
Mean±SD	4.5±3.2	4.3±3.2	4.1±3.4	4.6±3.1
Median (interquartile range)	4.0 (2.0–6.0)	4.0 (2.0–6.0)	4.0 (2.0–5.0)	4.0 (2.0–6.0)
Health medical service (1-yr prior ICH index) <sup>§</sup>				
No. of of specialty visits	9.9±19.3	9.3±14.8	9.7±14.1 <sup>†</sup>	8.8±15.6
No. of of family physician visits	3.2±6.0	2.7±4.4	2.6±4.0	2.9±4.9
No. of of emergency visits	3.9±3.8	3.6±3.6	3.6±3.6	3.6±3.7
Health hospital service (3-yr prior ICH index) <sup>§</sup>				
Proportion of all-cause hospital admission	360 (85.1)	226 (86.9)	129 (89.6)	97 (83.6)
No. of all-cause hospital admission	2.7±2.4	2.7±2.5	2.6±2.4	2.7±2.6
Hospital length of stay	11.2±10.8	7.5±6.9	7.0±6.6 <sup>†</sup>	8.1±7.3 <sup>†</sup>

Values are presented as mean±standard deviation or number (%) unless otherwise indicated.

OAC, oral anticoagulant; ICH, intracranial hemorrhage; DOAC, direct oral anticoagulant; ASA, acetylsalicylic acid; TIA, transient ischemic attack.

\*At the cohort entry; <sup>†</sup>P<0.05 in the comparison between the no OAC and the OAC partial exposure group; <sup>‡</sup>P<0.05 in the comparison between the no OAC and the OAC continuous exposure group; <sup>§</sup>Data source: Régie de l'Assurance Maladie du Québec (RAMQ) dataset; <sup>||</sup>The components of the scores are provided in Supplementary Tables.